Pfizer Inc. news

   Watch this stock
Showing stories 11 - 20 of about 200   

Articles published

PFE 30.71 -0.21 (-0.68%)
price chart
Can Celgene (NASDAQ:CELG) Earnings Leads...
Can Novartis AG (NYSE:NVS) and AstraZeneca PLC (NYSE:AZN) Can Novartis AG (NYSE:NVS) and AstraZene... Can Celgene (NASDAQ:CELG) Earnings Leads These Healthcare Stocks Up - Pfizer Inc Can Celgene (NASDAQ:CELG) Earnings Leads.
Pfizer Inc. (NYSE:PFE): Potential New Oncology Therapy
Pfizer Inc. (NYSE:PFE) announced in early February some positive results from a randomized Phase 2 trial of palbociclib in combination with letrozole (for blocking the synthesis of estrogen) in post-menopausal women with estrogen receptor (ER) positive ...
Today's Market: Other Potential Buyout Targets For Pfizer
Discuss Pfizer and its need to do a deal. Talk potential names in the biotech space which would make attractive buyout candidates.
Related articles »  
Promotional Campaigns, Equity Awards, Stock Price Movements, New Launches ...
Today, Analysts Review released its analysts' notes regarding Pfizer Inc. (NYSE:PFE) , Intuitive Surgical, Inc. (NASDAQ:ISRG) , HCA Holdings Inc. (NYSE:HCA) , General Electric Company (NYSE:GE) and Deere & Company (NYSE:DE) .
Related articles »  
UPDATE 2-Teva settles patent suit with Pfizer over Celebrex
The deal settles Pfizer's patent infringement lawsuit against Teva. The U.S. drugmaker has also sued other generic drugmakers, including Mylan Inc and Actavis Inc, which are seeking U.S. regulatory approval to sell their own versions of Celebrex.
Company Update: Pfizer Inc (NYSE:PFE) � Teva settles patent suit with Pfizer ...  Jutia Group
Teva, Pfizer settle patent lawsuit over blockbuster painkiller  Reuters India
Related articles »  
Pfizer Inc. (NYSE:PFE): Breakthroughs in Vaccines and Oncology
Tomahawk, WI 03/27/2014 (Basicsmedia) - While Pfizer Inc. (NYSE:PFE) got some bad news when its Celebrex patent was invalidated by a U.S.
Pfizer Eyes AstraZeneca For Cancer Pipeline, Cost Savings
The Sunday Times reported yesterday that pharma giant Pfizer Inc. (NYSE:PFE) had recently made a $101 billion bid for smaller rival AstraZeneca plc (ADR) (NYSE:AZN) (LON:AZN).
Dow Today: Pfizer (PFE) Lower
Pfizer has a market cap of $198.2 billion and is part of the health care sector and drugs industry. Shares are up 0.9% year-to-date as of Wednesday's close.
Related articles »  
Actavis Settles Celebrex Case With Pfizer -- Update
Actavis PLC and Pfizer Inc. said they settled all patent litigation over the generic version of painkiller Celebrex, which may allow Actavis to start marketing its version before the end of the year.
Actavis Reaches Deal With Pfizer To Sell Generic Celebrex  Law360 (subscription)
Actavis Announces Celebrex� Patent Challenge Settlement  MarketWatch
Related articles »  
Law firm shakes down Pfizer
Kaplan Fox & Kilsheimer extract a $190M settlement from Pfizer (PFE +2%) for allegedly forcing consumers to pay higher prices for Neurotonin and Gabapentin from late 2002 until mid-2008.